See more : Green Dot Corporation (GDOT) Income Statement Analysis – Financial Results
Complete financial analysis of Tibet AIM Pharm. Inc. (002826.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tibet AIM Pharm. Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Prodigy Public Company Limited (PDG.BK) Income Statement Analysis – Financial Results
- Corcept Therapeutics Incorporated (0I3Q.L) Income Statement Analysis – Financial Results
- Stanley Electric Co., Ltd. (STAEF) Income Statement Analysis – Financial Results
- TomCo Energy Plc (TOM.L) Income Statement Analysis – Financial Results
- Nihar Info Global Limited (NIHARINF.BO) Income Statement Analysis – Financial Results
Tibet AIM Pharm. Inc. (002826.SZ)
About Tibet AIM Pharm. Inc.
Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 667.04M | 856.73M | 725.46M | 602.62M | 553.26M | 488.77M | 380.29M | 451.92M | 347.00M | 290.73M | 221.11M |
| Cost of Revenue | 325.59M | 480.56M | 464.96M | 385.89M | 370.92M | 332.66M | 108.80M | 131.55M | 107.25M | 102.27M | 90.84M |
| Gross Profit | 341.45M | 376.17M | 260.50M | 216.72M | 182.33M | 156.11M | 271.49M | 320.37M | 239.75M | 188.46M | 130.27M |
| Gross Profit Ratio | 51.19% | 43.91% | 35.91% | 35.96% | 32.96% | 31.94% | 71.39% | 70.89% | 69.09% | 64.82% | 58.92% |
| Research & Development | 19.66M | 13.35M | 11.39M | 6.85M | 5.00M | 16.41M | 3.59M | 2.18M | 5.54M | 7.47M | 11.14M |
| General & Administrative | 16.83M | 24.70M | 29.25M | 18.50M | 18.52M | 13.06M | 14.10M | 19.98M | 16.51M | 10.93M | 12.68M |
| Selling & Marketing | 221.24M | 270.67M | 172.57M | 142.87M | 111.46M | 99.18M | 182.16M | 215.96M | 155.53M | 123.48M | 82.62M |
| SG&A | 291.33M | 295.37M | 201.81M | 161.37M | 129.97M | 112.24M | 196.25M | 235.94M | 172.04M | 134.42M | 95.31M |
| Other Expenses | 6.96M | 11.29M | 4.70M | 3.40M | -38.67K | 2.14M | 2.82M | 16.52M | 11.52M | 12.62M | 12.10M |
| Operating Expenses | 317.95M | 320.01M | 217.91M | 171.62M | 134.93M | 131.08M | 205.33M | 263.31M | 191.83M | 156.10M | 117.98M |
| Cost & Expenses | 643.53M | 800.58M | 682.86M | 557.52M | 505.85M | 463.75M | 314.13M | 394.86M | 299.08M | 258.37M | 208.82M |
| Interest Income | 2.75M | 2.45M | 2.01M | 1.01M | 632.17K | 593.69K | 832.39K | 114.81K | 55.79K | 73.46K | 63.47K |
| Interest Expense | 1.18M | 810.56K | 843.14K | 1.62M | 2.71M | 1.38M | 551.27K | 3.42M | 845.51K | 1.47M | 2.95M |
| Depreciation & Amortization | 24.14M | 24.49M | 25.45M | 16.74M | 10.91M | 9.59M | 8.45M | 7.54M | 3.37M | 3.48M | 3.42M |
| EBITDA | 48.91M | 80.21M | 76.36M | 65.76M | 61.44M | 39.85M | 76.99M | 75.69M | 61.02M | 47.82M | 32.72M |
| EBITDA Ratio | 7.33% | 9.77% | 9.73% | 11.21% | 10.84% | 8.29% | 21.23% | 17.61% | 18.26% | 16.81% | 14.03% |
| Operating Income | 23.50M | 55.73M | 48.64M | 43.13M | 47.70M | 26.86M | 65.10M | 47.15M | 45.46M | 29.97M | 14.24M |
| Operating Income Ratio | 3.52% | 6.50% | 6.70% | 7.16% | 8.62% | 5.49% | 17.12% | 10.43% | 13.10% | 10.31% | 6.44% |
| Total Other Income/Expenses | 94.61K | 973.24K | 1.38M | 4.22M | 33.62K | 2.14M | 2.82M | -5.32M | 10.66M | 12.57M | 11.96M |
| Income Before Tax | 23.60M | 56.70M | 50.01M | 47.35M | 47.74M | 28.99M | 67.92M | 63.20M | 56.12M | 42.53M | 26.19M |
| Income Before Tax Ratio | 3.54% | 6.62% | 6.89% | 7.86% | 8.63% | 5.93% | 17.86% | 13.98% | 16.17% | 14.63% | 11.85% |
| Income Tax Expense | 7.87M | 10.59M | 6.54M | 6.26M | 10.41M | 3.74M | 7.44M | 7.84M | 6.09M | 8.68M | 4.37M |
| Net Income | 15.39M | 44.14M | 42.48M | 41.09M | 37.33M | 25.26M | 60.48M | 55.36M | 50.03M | 32.37M | 19.71M |
| Net Income Ratio | 2.31% | 5.15% | 5.86% | 6.82% | 6.75% | 5.17% | 15.90% | 12.25% | 14.42% | 11.14% | 8.91% |
| EPS | 0.08 | 0.23 | 0.22 | 0.22 | 0.20 | 0.13 | 0.32 | 0.38 | 0.37 | 0.24 | 0.39 |
| EPS Diluted | 0.08 | 0.23 | 0.22 | 0.22 | 0.20 | 0.13 | 0.32 | 0.38 | 0.37 | 0.24 | 0.39 |
| Weighted Avg Shares Out | 192.33M | 190.68M | 190.21M | 189.72M | 189.72M | 189.72M | 188.99M | 145.68M | 135.22M | 134.89M | 191.19M |
| Weighted Avg Shares Out (Dil) | 192.33M | 190.68M | 190.21M | 189.72M | 189.72M | 194.27M | 188.99M | 145.68M | 135.22M | 134.89M | 191.19M |
Source: https://incomestatements.info
Category: Stock Reports